BioSpace News Archive

Deals

FTC Will Have More Time to Review Novo’s $16.5B Catalent Buy

The FTC and the U.S. Department of Justice’s antitrust division will have another 30 days to examine Novo Nordisk Foundation’s acquisition of contract manufacturer Catalent, according to an SEC filing.

April 5, 2024
·
1 min read
·
Tyler Patchen
AACR 2024: What Cancer Researchers Are Talking About

With the American Association for Cancer Research’s annual conference well underway, data from vaccines and other products targeting tough-to-treat cancers have dominated the program.

April 5, 2024
·
19 min read
·
Greg Slabodkin, Heather McKenzie and Tyler Patchen
Deals

Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials

Contineum Therapeutics priced its initial public offering Friday, scaling back its expectations for gross proceeds of $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.

April 5, 2024
·
2 min read
·
Nick Paul Taylor
Policy

US National Security, China and Biotechnology in 2024

Recent warnings about Chinese biopharma partners from members of Congress and U.S. intelligence officials have reached a fever pitch in Washington.

April 5, 2024
·
4 min read
·
Greg Slabodkin
FDA

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment

The approvals, third line for BMS and 2seventy Bio’s Abecma and second line for J&J and Legend Biotech’s Carvykti, represent a new class of therapy for these blood cancer patients.

April 5, 2024
·
3 min read
·
Heather McKenzie and Nadia Bey
Drug Development

Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS

Seeking a potential slice of the challenging KRAS market, Merck has launched a Phase III NSCLC trial of its oral G12C inhibitor MK-1084, in combination with Keytruda, in pursuit of Amgen and Bristol Myers Squibb.

April 5, 2024
·
2 min read
·
Tristan Manalac
Drug Development

AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer

Following disappointing Phase III results in less aggressive non-small cell lung cancer, AstraZeneca on Friday announced that Imfinzi improved progression-free and overall survival in patients with limited-stage small cell lung cancer.

April 5, 2024
·
2 min read
·
Tristan Manalac
Drug Development

Novartis to File for Pluvicto Label Expansion After Promising Phase III Data

Following clearer overall survival data from the PSMAfore trial, Novartis on Thursday affirmed plans to file for a prostate cancer label expansion for its targeted radioligand therapy Pluvicto later this year.

April 5, 2024
·
2 min read
·
Tristan Manalac
Drug Development

5 Successful Phase III Oncology Trials in Q1

2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.

April 5, 2024
·
5 min read
·
Nsisong Asanga
Business

Boehringer Ingelheim Cuts Staff Due to Low Humira Biosimilar Sales: Reuters

Due to slow uptake of its Humira biosimilar Cyltezo in the U.S., Boehringer Ingelheim is laying off an undisclosed number of its sales employees, Reuters reported on Thursday.

April 5, 2024
·
2 min read
·
Tristan Manalac